IL-12 Induces T Helper 1-Directed Antitumor Response

Journal of Immunology

Volumn 158, Issue 7, 1997, Pages 3359-3365

  Tsung, Kangla ^b   Meko, Jennifer B ^b   Peplinski, Gary R ^b   Tsung, Ying L ^b   Norton, Jeffrey A ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12; RECOMBINANT PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FIBROSARCOMA; GENETICS; IMMUNOLOGY; MOUSE; PATHOLOGY; TH1 CELL; VACCINIA VIRUS;

ANIMALS; CYTOKINES; FIBROSARCOMA; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TH1 CELLS; VACCINIA VIRUS;

EID: 0031110368     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
2. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
3. Mu, J., J-P. Zou, N. Yamamoto, T. Tsutsui, X-G. Tai, M. Kobayashi, S. Herrmann, H. Fujiwara, and T. Hamaoka. 1995. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 55:4404.
4. Noguchi, Y., E. C. Richards, Y-T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
5. Zou, J-P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Herrmann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
6. Rakhmilevich, A. L., J. Turner, M. J. Ford, D. McCabe, W. H. Sun, P. M. Sondel, K. Grota, and N-S. Yang. 1996. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl. Acad. Sci. USA 93:6291.
7. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12. J. Immunol. 155:1393.
8. Tan, J., C. A. Newton, J. Y. Djeu, D. E. Gutsch, A. E. Chang, N-S. Yang, T. W. Klein, and H. Yu. 1996. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 56:3399.
9. Meko, J. B., J. H. Yim, K. Tsung, and J. A. Norton. 1995. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. 55:4765.
10. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. Zeh III, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466.
11. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
12. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad Sci. USA 90:3539.
13. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, and M. Murphy. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol. 6:157.
14. Car, B. D., V. M. Eng, B. Schnyder, M. LeHir, A. N. Shakhov, G. Woerly, S. Huang, M. Aguet, T. D. Anderson, and B. Ryffel. 1995. Role of interferon-γ in interleukin 12-induced pathology in mice. Am. J. Pathol. 147:1693.
15. Karupiah, G., Q-W. Xie, R. M. L. Buller, C. Nathan, C. Duarte, and J. D. Mac-Micking. 1993. Inhibition of viral replication by interferon-γ-induced nitric oxide synthase. Science 261:1445.
16. Keller, R., M. Geiges, and R. Keist. 1990. L-Arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res. 50:1421.
17. Xie, K., S. Huang, Z. Dong, S-H. Juang, M. Gutman, Q-W. Xie, C. Nathan, and I. J. Fidler. 1995. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181:1333.
18. Stuehr, D. J., and C. F. Nathan. 1989. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169:1543.
19. Drapier, J-C., and J. B. Hibbs. 1986. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells: inhibition involves the iron-sulfur prosthetic group and is reversible. J. Clin. Invest. 78:790.
20. Haddad, E. K., A. J. Duclos, and M. G. Baines. 1995. Early embryo loss is associated with local production of nitric oxide by decidual mononuclear cells. J. Exp. Med. 182:1143.
21. Kwon, N. S., D. J. Stuehr, and C. F. Nathan. 1991. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J. Exp. Med. 174: 761.
22. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
23. Leist, T. P., M. Eppler, and R. M. Zinkernagel. 1989. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice. J. Virol. 63:2813.
24. + T cells is dependent on interferon-γ. Lymphokine Cytokine Res. 10:353.
25. Campbell, I. L., T. W. H. Kay, L. Oxbrow, and L. C. Harrison. 1991. Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87:739.
26. Debray-Sachs, M., C. Carnaud, C. Boitard, H. Cohen, I. Gresser, P. Bedossa, and J-F. Bach. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFN γ. J. Autoimmun. 4:237.
27. Belosevic, M., D. S. Finbloom, P. H. Van der meide, M. V. Slayter, and C. A. Nacy. 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.
28. Bradley, L. M., K. Yoshimoto, and S. L. Swain. 1995. The cytokines IL-4, IFN-γ, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro. J. Immunol. 155:1713.
29. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505.
30. + T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent. Int. Immunol. 5:1119.
31. Bradley, L. M., D. K. Dalton, and M. Croft. 1996. A direct role for IFN-γ in regulation of Th1 cell development. J. Immunol. 157:1350.
32. Wang, Z-E., S. Zheng, D. B. Corry, D. K. Dalton, R. A. Seder, S. L. Reiner, and R. M. Locksley. 1994. Interferon γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc. Natl. Acad. Sci. USA 91:12932.
33. Manetti, R., P. Parronchi, M. G. Giudizi, M-P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
34. Windhagen, A., D. E. Anderson, A. Carrizosa, R. E. Williams, and D. A. Hafler. 1996. IL-12 induces human T cells secreting IL-10 with IFN-γ. J. Immunol. 157:1127.
35. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:10188.
36. Gerosa, F., C. Paganin, D. Peritt, F. Paiola, M. T. Scupoli, M. Aste-Amezaga, I. Frank, and G. Trinchieri. 1996. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-γ and interleukin-10. J. Exp. Med. 183:2559.
37. Segal, B. M., and E. M. Shevach. 1996. IL-12 unmasks latent autoimmune disease in resistant mice. J. Exp. Med. 184:771.
38. Cox, G. W., G. Melillo, U. Chattopadhyay, D. Mullet, R. H. Fertel, and L. Varesio. 1992. Tumor necrosis factor-α-dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2-induced murine macrophage tumoricidal activity. J. Immunol. 149:3290.
39. Belosevic, M., D. S. Finbloom, M. S. Meltzer, and C. A. Nacy. 1990. A cofactor for induction of activated macrophage resistance to infection. J. Immunol. 145: 831.
40. Stout, R. D., and K. Bottomly. 1989. Antigen-specific activation of effector macrophages by IFN-γ producing (Th1) T cell clones, failure of IL-4-producing (Th2) T cell clones to activate effector function in macrophages. J. Immunol. 142:760.
41. Wigginton, J. M., D. B. Kuhns, T. C. Back, M. J. Brunda, R. H. Wiltrout, and G. W. Cox. 1996. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131.
42. Zinkernagel, R. M., and A. Althage. 1977. Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled. J. Exp. Med. 145:644.
43. + T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia vims protection than CD4-dependent IL. J. Immunol. 146:4301.
44. Kündig, T. M., H. Hengartner, and R. M. Zinkernagel. 1993. T cell-dependent IFN-γ exerts an antiviral effect in the central nervous system but not in peripheral solid organs. J. Immunol. 150:2316.
45. Kägi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Bürki, R. M. Zinkernagel, and H. Hengartner. 1995. The roles of perform- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 25:3256.
46. North, R. J., and I. Bursuker. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. J. Exp. Med. 159:1295.
47. + T lymphocytes. J. Immunol. 155:111.
48. + T cells through an effect on antigen-presenting cells. J. Immunol. 154:2578.
49. h1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur. J. Immunol. 21:2489.
50. Modolell, M., I. M. Corraliza, F. Link, G. Soler, and K. Eichmann. 1995. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25: 1101.
51. Taub, D. D., and G. W. Cox. 1995. Murine Th1 and Th2 cell clones differentially regulate macrophage nitric oxide production. J. Leukocyte Biol. 58:80.
52. Rothe, H., A. Faust, U. Schade, R. Kleemann, G. Bosse, T. Hibino, S. Martin, and H. Kolb. 1994. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 37:1154.
53. Tao, X., and R. D. Stout. 1993. T cell-mediated cognate signaling of nitric oxide production by macrophages: requirements for macrophage activation by plasma membranes isolated from T cells. Eur. J. Immunol. 23:2916.
54. Tian, L., R. J. Noelle, and D. A. Lawrence. 1995. Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur. J. Immunol. 25:306.